Table 4.

Muscle effects

	Daptomycin (n = 45) n (%)	Vancomycin/gentamicin (n = 43) n (%)	P valuea
Reported clinical adverse events
CPK increased	2 (4)	0	0.49
musculoskeletal events	11 (24)	20 (47)	0.04
discontinued therapy due to CPK	1 (2)	0	>0.99
Lab abnormalities
CPK shift from normal to >500 IU/L	4/38 (11)	0/36	0.12

CPK, creatine phosphokinase.

^aFisher’s exact test.